10x Genomics, Inc. (TXG)
Healthcare • Medical Devices
StockNasdaqGSUnited StatesUS88025U1097
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by 10x Genomics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:33. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | -0.04 | — | — | Upcoming |
| 05 Nov 2026 16:00 | -0.02 | 0.03 | +240.3% | Beat |
| 06 Aug 2026 16:00 | -0.02 | 0.03 | +258.4% | Beat |
| 07 May 2026 16:00 | -0.06 | 0.07 | +219.2% | Beat |
| 12 Feb 2026 16:00 | -0.04 | 0.07 | +276.3% | Beat |
| 06 Nov 2025 16:00 | -0.07 | -0.02 | +67.4% | Beat |
| 07 Aug 2025 16:00 | -0.08 | 0.48 | +702.1% | Beat |
| 08 May 2025 16:00 | -0.29 | -0.10 | +64.9% | Beat |
| 12 Feb 2025 16:00 | -0.11 | -0.14 | -27.1% | Miss |
| 29 Oct 2024 16:00 | -0.26 | -0.02 | +94.1% | Beat |
| 08 Aug 2024 16:00 | -0.23 | 0.01 | +102.2% | Beat |
| 30 Apr 2024 16:00 | -0.39 | -0.20 | +48.3% | Beat |
| 15 Feb 2024 16:00 | -0.02 | 0.08 | +502.5% | Beat |
| 02 Nov 2023 16:00 | -0.04 | -0.10 | -141.0% | Miss |
| 03 Aug 2023 16:00 | -0.05 | -0.14 | -186.4% | Miss |
| 03 May 2023 16:00 | -0.16 | -0.07 | +54.7% | Beat |
| 15 Feb 2023 16:00 | -0.20 | 0.21 | +202.1% | Beat |
| 02 Nov 2022 16:00 | -0.24 | -0.07 | +69.3% | Beat |
| 08 Aug 2022 16:00 | -0.30 | -0.25 | +16.5% | Beat |
| 04 May 2022 16:00 | -0.33 | -0.14 | +56.8% | Beat |
| 16 Feb 2022 16:00 | -0.03 | -0.16 | -380.1% | Miss |
| 03 Nov 2021 16:00 | -0.21 | -0.15 | +28.6% | Beat |
| 04 Aug 2021 16:00 | -0.23 | -0.11 | +53.9% | Beat |
| 05 May 2021 16:00 | -0.19 | -0.11 | +43.6% | Beat |
| 17 Feb 2021 16:00 | -0.07 | -0.08 | -11.0% | Miss |
| 10 Nov 2020 16:00 | -0.31 | -0.25 | +20.0% | Beat |
| 11 Aug 2020 16:00 | -0.49 | -0.41 | +16.3% | Beat |
| 11 May 2020 16:00 | -0.13 | -0.20 | -52.4% | Miss |
| 18 Feb 2020 16:00 | -0.13 | -0.07 | +48.0% | Beat |
| 07 Nov 2019 16:00 | -0.10 | -0.33 | -235.9% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 642.8M | +5.2% | -43.5M | -6.8% | -0.35 | +77.0% | 130.1M |
| 2024 | 610.8M | -1.3% | -182.6M | -29.9% | -1.52 | +30.3% | -6.7M |
| 2023 | 618.7M | +19.8% | -255.1M | -41.2% | -2.18 | -49.3% | -64.7M |
| 2022 | 516.4M | — | -166M | -32.1% | -1.46 | — | -165.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 60.46 | 68.94 | 53.00 | 58.41 | -1.47% | 10,182,432 | |
| 02 Nov 2026 – 06 Nov 2026 | 70.31 | 71.00 | 55.50 | 59.28 | -15.45% | 21,218,400 | |
| 26 Oct 2026 – 30 Oct 2026 | 70.81 | 87.82 | 67.42 | 70.11 | -2.01% | 15,654,300 | |
| 19 Oct 2026 – 23 Oct 2026 | 71.48 | 77.55 | 67.25 | 71.55 | +2.42% | 14,925,600 | |
| 12 Oct 2026 – 16 Oct 2026 | 79.18 | 80.47 | 67.52 | 69.86 | -13.38% | 19,957,500 | |
| 05 Oct 2026 – 09 Oct 2026 | 93.50 | 102.81 | 70.94 | 80.65 | -13.74% | 30,916,800 | |
| 28 Sep 2026 – 02 Oct 2026 | 86.00 | 95.16 | 84.27 | 93.50 | +9.09% | 16,960,300 | |
| 21 Sep 2026 – 25 Sep 2026 | 79.15 | 86.16 | 74.60 | 85.71 | +11.89% | 17,287,100 | |
| 14 Sep 2026 – 18 Sep 2026 | 67.04 | 79.94 | 64.73 | 76.60 | +11.68% | 16,372,300 | |
| 08 Sep 2026 – 11 Sep 2026 | 61.36 | 69.67 | 61.36 | 68.59 | +9.48% | 10,406,100 | |
| 253 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- 10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study (opens in a new tab) Zacks · 12 Nov 2026 17:27
- What Makes 10x Genomics (TXG) a Strong Position Ahead of Its H2 2026 Atera Launch? (opens in a new tab) Insider Monkey · 12 Nov 2026 16:42
- 10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial (opens in a new tab) Benzinga · 10 Nov 2026 10:07
- TXG Q3 2026 deep dive: spatial platform launch and AI-driven demand shape outlook (opens in a new tab) StockStory · 10 Nov 2026 09:57
- JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65 (opens in a new tab) Benzinga · 09 Nov 2026 16:48
- Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70 (opens in a new tab) Benzinga · 09 Nov 2026 11:18
- 10x Genomics (TXG) Could Be 24% Undervalued After Raising Its 2026 Revenue Outlook (opens in a new tab) Simply Wall St. · 07 Nov 2026 11:11
- UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 (opens in a new tab) Benzinga · 06 Nov 2026 19:14
- Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60 (opens in a new tab) Benzinga · 06 Nov 2026 17:23
- 10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 17:13
- 10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis (opens in a new tab) Zacks · 06 Nov 2026 15:54
- TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook (opens in a new tab) Zacks · 06 Nov 2026 14:32
- What 10x Genomics (TXG) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 06 Nov 2026 14:14
- 10x Genomics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 06 Nov 2026 13:30
- Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68 (opens in a new tab) Benzinga · 06 Nov 2026 08:35
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 59.10 USD
- Market cap
- 7.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Devices
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow TXG and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.